Oxurion NV OXUR-BE:Euronext Brussels

RT Quote | Exchange | EUR
Last | 4:41 PM CEST
0.0001UNCH (UNCH)
Volume
26,144,998
52 week range
0.00 - 0.01
Loading...
  • Open0.0001
  • Day High0.0002
  • Day Low0.0001
  • Prev Close0.0001
  • 52 Week High0.01
  • 52 Week High Date05/30/23
  • 52 Week Low0.00
  • 52 Week Low Date05/09/24

Key Stats

  • Market Cap752,850.75
  • Shares Out3,489.46M
  • 10 Day Average Volume82.19M
  • Dividend-
  • Dividend Yield-
  • Beta1.13
  • YTD % Change-

KEY STATS

  • Open0.0001
  • Day High0.0002
  • Day Low0.0001
  • Prev Close0.0001
  • 52 Week High0.01
  • 52 Week High Date05/30/23
  • 52 Week Low0.00
  • 52 Week Low Date05/09/24
  • Market Cap752,850.75
  • Shares Out3,489.46M
  • 10 Day Average Volume82.19M
  • Dividend-
  • Dividend Yield-
  • Beta1.13
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.02
  • P/E (TTM)-0.00
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oxurion NV

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States....
Pascal Ghoson
Chief Executive Officer, Chief Financial Officer, Director
Address
Gaston Geenslaan 1
Leuven (louvain)
3001
Belgium